Navigation Links
Senokot(R) Tablets Undergo a Natural Makeover
Date:8/6/2009

STAMFORD, Conn., Aug. 6 /PRNewswire/ -- The Purdue Products L.P. line of laxatives unveiled its newest addition on June 28, at the National Association of Chain Drug Stores (NACDS) 2009 Marketplace Conference, in Boston. Newly reformulated Senokot(R) Tablets are not chemically processed, and the primary ingredient is the deseeded pod of the senna plant.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090806/NY57748 )

"We've always been proud of the fact that Senokot(R) Tablets are such a trusted laxative brand," says Charlene Bailey, Director, Product Management, Purdue Products L.P. "But we're really excited to give consumers something new - especially at a time when interest is so high in natural products." The new Senokot(R) Tablets will be available in pharmacies (drug, food and mass merchandisers) nationwide in October 2009.

Purdue will support the introduction with a comprehensive media plan that includes national television advertising, retail account programs, coupons, and rebates. In addition, the contemporary design for the brand will not only stand out on-shelf, but will also reinforce Senokot(R) and Senokot-S(R) Tablets as a natural choice for today's health-minded consumers.

With more than four million Americans reporting that they suffer from frequent constipation(1), this common digestive health complaint can be attributed to many causes. Stress, poor diet and lack of exercise can all take a toll on the body. The new, reformulated Senokot(R) and Senokot-S(R) Tablets provide an effective option that pharmacists and other healthcare professionals can feel good about recommending to consumers to treat occasional constipation associated with diet or lifestyle.

The new Senokot(R) and Senokot-S(R) Tablets will be hitting the shelves in the fall, joining the other Purdue Laxative brands, including Colace (R) Capsules and Peri-Colace(R) Tablets and rounding out the company's comprehensive offerings for relief for occasional constipation.

The Purdue Products L.P. Line of Laxatives

Senokot(R) Tablets and Colace(R) Capsules have been recommended by doctors and pharmacists for more than 50 years for effective, gentle and safe relief from occasional constipation. Colace(R) Capsules, the #1 recommended stool softener brand by doctors and pharmacists, relieves occasional constipation that may be associated with certain medical conditions. Senokot (R)Tablets provide gentle, yet effective relief for occasional constipation associated with diet or lifestyle. The Purdue laxative portfolio includes: Colace(R) Capsules, Peri-Colace(R) Tablets, Senokot(R) Tablets, Senokot-S(R) Tablets and SenokotXTRA(R) Tablets. The Purdue laxative portfolio is dedicated to providing consumers with specific solutions to the various types of occasional constipation that can occur as a part of everyday life.

(1) National Institute of Diabetes and Digestive and Kidney Diseases. (2007). National Digestive Diseases Information Clearing House: Constipation. Retrieved January 26, 2009, from http://digestive.niddk.nih.gov/ddiseases/pubs/constipation/Constipation.pdf

    Press Contact:
    Vicky Toporovsky
    Pollock Communications
    646.277.8719
    vtoporovsky@pollock-pr.com


'/>"/>
SOURCE Purdue Products L.P.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
2. Actavis Launches Carvedilol Tablets in the U.S.
3. Mylan Announces Final FDA Approval for Carvedilol Tablets
4. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
5. Actavis Launches Amlodipine Tablets in the U.S.
6. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
7. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
8. KV Pharmaceutical Announces FDA Approval for Morphine ER 100 mg and 200 mg Tablets
9. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
10. Ranbaxy Receives Tentative Approval For Valsartan Tablets
11. Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, ... organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
Breaking Medicine Technology: